论著

液相色谱串联质谱检测尿黏多糖在黏多糖贮积症患者诊断与随访中的应用

  • 占霞 ,
  • 高晓岚 ,
  • 季文君 ,
  • 常思宇 ,
  • 刘丹 ,
  • 张惠文
展开
  • 1.上海交通大学医学院附属新华医院儿内分泌遗传代谢科 上海市儿科医学研究所(上海 200092)
    2.上海爱博才思分析仪器贸易有限公司(上海 200050)

收稿日期: 2024-01-23

  网络出版日期: 2024-05-10

基金资助

上海市卫生健康委员会临床专项(202240361);上海市“科技创新行动计划”医学创新研究专项(20MC1920400)

Detection of urine glycosaminoglycans by liquid chromatography-tandem mass spectrometry in the diagnosis and follow-up of patients with mucopolysaccharidosis

  • Xia ZHAN ,
  • Xiaolan GAO ,
  • Wenjun JI ,
  • Siyu CHANG ,
  • Dan LIU ,
  • Huiwen Zhang
Expand
  • 1. Department of Pediatric Endocrinology and Genetics, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
    2. Shanghai AB Sciex Analytical Instrument Trading Co. Ltd, Shanghai 20050, China

Received date: 2024-01-23

  Online published: 2024-05-10

摘要

目的 运用液相色谱串联质谱(LC-MS/MS)技术建立尿液中硫酸软骨素(CS)、硫酸皮肤素(DS)和硫酸乙酰肝素(HS)含量的检测方法,探究该方法在黏多糖贮积症(MPS)患者诊断及治疗随访中的应用。方法 收集20例MPS患儿及37例正常儿童尿液样本,测定尿液中CS、DS和HS等浓度。尿样氮气吹干,盐酸甲醇衍生化,再次氮气吹干,复溶后LC-MS/MS分析;评价方法的线性、定量限、精密度、加样回收率和基质效应。结果 LC-MS/MS检测CS、DS和HS的线性均大于0.99。CS、DS和HS的定量下限依次为:0.5、1.0和1.0 mg/L。批内不精密度为1.9%~10.4%,批间不精密度为2.6%~9.8%。加标回收率为85.6%~110.4%,相对基质效应为84.9%~115.5%。CS、DS和HS在正常儿童尿液中呈正态分布,以 x+1.64 SD计算正常儿童尿液中的参考区间上限,分别为16.5、1.8、1.4 mg/mmol。通过分析MPS患儿尿液黏多糖特点,LC-MS/MS法能有效检出MPS I、MPS Ⅱ、MPS Ⅲ和MPS Ⅵ等MPS患儿。已接受造血干细胞移植的MPS Ⅰ和MPS Ⅱ患儿尿DS、HS水平降低。结论 LC-MS/MS检测尿黏多糖性能良好,有望用于MPS患者的精准诊断和治疗随访监测。

本文引用格式

占霞 , 高晓岚 , 季文君 , 常思宇 , 刘丹 , 张惠文 . 液相色谱串联质谱检测尿黏多糖在黏多糖贮积症患者诊断与随访中的应用[J]. 临床儿科杂志, 2024 , 42(5) : 399 -406 . DOI: 10.12372/jcp.2024.24e0050

Abstract

Objective To establish a method to determine chondroitin sulfate (CS), dermatan sulfate (DS) and heparan sulfate (HS) in urine by liquid chromatography tandem mass spectrometry (LC-MS/MS), and to investigate the application of urine glycosaminoglycans detection in the diagnosis and follow-up of mucopolysaccharidosis (MPS) patients. Methods Twenty urine samples from MPS patients and 37 urine samples from normal children were collected, and glycosaminoglycans levels in these samples were determined. Urine samples were added and dried under nitrogen. Then the samples were derivatized with methanol hydrochloride and dried under nitrogen. After reconstituted, the glycosaminoglycans were analyzed by LC-MS/MS. The linearity, limit of quantification, precision, spiked recoveries, and matrix effect were evaluated. Results The linearity of CS, DS and HS by LC-MS/MS was>0.99. The limits of quantification for CS, DS and HS were 0.5 mg/L, 1 mg/L and 1 mg/L, respectively; the intra-day imprecision ranged from 1.9% to 10.4%, and the inter-day imprecision ranged from 2.6% to 9.8%; and the recovery ranged from 85.6% to 110.4%, the relative matrix effect ranged from 84.9% to 115.5%. CS, DS and HS in urine samples of normal children were normally distributed, then the upper limit of reference interval were preliminarily determined by mean+1.64 SD, which were 16.5 mg/mmol, 1.8 mg/mmol and 1.4 mg/mmol, respectively. Urine GAGs of MPS patients were analyzed, the LC-MS/MS method was effective in detecting MPSⅠ, MPSⅡ, MPSⅢ and MPSⅥ patients. Urine samples of MPSⅠ or MPSⅡ patients who had hematopoietic stem cell transplantation showed reduced DS and HS concentration. Conclusion LC-MS/MS has good performance in detecting urinary mucopolysaccharides and is expected to be used for accurate diagnosis and treatment follow-up monitoring of MPS patients.

参考文献

[1] Peterson S, Liu J. Deciphering mode of action of heparanase using structurally defined oligosaccharides[J]. J Biol Chem, 2012, 287(41): 34836-34843.
[2] Kakkis E, Marsden D. Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses[J]. Mol Genet Metab, 2020, 130(1):7-15.
[3] Bobillo Lobato J, Jiménez Hidalgo M, Jiménez Jiménez LM. Biomarkers in lysosomal storage diseases[J]. Diseases, 2016, 4(4):40-57.
[4] 张惠文, 王瑜, 叶军, 等. 黏多糖贮积症47例的常见酶学分型[J]. 中华儿科杂志, 2009, 47(4): 276-280.
[5] Gray G, Claridge P, Jenkinson L, et al. Quantitation of urinary glycosaminoglycans using dimethylene blue as a screening technique for the diagnosis of mucopolysaccharidoses: an evaluation[J]. Ann Clin Biochem, 2007, 44: 360-363.
[6] 雷红林, 叶军, 张惠文, 等. 35例黏多糖贮积症Ⅳ型患儿临床特点及酶学诊断[J]. 临床儿科杂志, 2012, 30(5): 442-445.
[7] de Jong JG, Wevers RA, Laarakkers C, et al. Dimethylmethylene blue-basedspectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses[J]. Clin Chem, 1989, 35 (7): 1472-1477.
[8] 中华医学会检验医学分会,卫生计生委临床检验中心. 液相色谱-质谱临床应用建议[J]. 中华检验医学杂志, 2017, 40(10): 770-779.
[9] 中国医师协会检验医师分会临床质谱检验医学专业委员会. 液相色谱串联质谱临床检测方法的开发与验证[J]. 检验医学, 2019, 34(3): 189-196.
[10] 常思宇, 高晓岚, 王瑜, 等. 溶酶体贮积症1 520例疾病谱分析[J]. 中华实用儿科临床杂志, 2023, 38(1) : 60-63.
[11] Lin HY, Tu RY, Chern SR, et al. Identification and functional characterization of IDS gene mutations underlying taiwanese hunter syndrome (Mucopolysaccharidosis Type II)[J]. Int J Mol Sci, 2019, 21(1):114-131.
[12] Lamanna WC, Lawrence R, Sarrazin S, et al. Secondary storage of dermatan sulfate in Sanfilippo disease[J]. J Biol Chem, 2011, 286(9): 6955-6962.
[13] 中华医学会儿科学分会内分泌遗传代谢学组. 黏多糖贮积症Ⅱ型临床诊断与治疗专家共识[J]. 中华儿科杂志, 2021, 59(6): 446-451.
[14] 中华医学会儿科学分会血液学组. 异基因造血干细胞移植治疗黏多糖贮积症儿科专家共识[J]. 中国小儿血液与肿瘤杂志, 2017, 22(5): 227-230.
[15] 中华医学会儿科学分会内分泌遗传代谢学组. 黏多糖贮积症Ⅰ型诊疗专家共识(2022)[J]. 中华儿科杂志, 2023, 61(3) : 203-208.
[16] Bigger BW, Begley DJ, Virgintino D, et al. Anatomical changes and pathophysiology of the brain in mucopoly-saccharidosis disorders[J]. Mol Genet Metab, 2018, 125(4): 322-331.
[17] Guffon N, Bertrand Y, Forest I, et al. Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years[J]. J Pediatr, 2009, 154(5): 733-737.
[18] Tanaka A, Okuyama T, Suzuki Y, et al. Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan[J]. Mol Genet Metab, 2012, 107(3): 513-520.
[19] Li R, Tian L, Gao Q, et al. Establishment of cutoff values for newborn screening of six lysosomal storage disorders by tandem mass spectrometry[J]. Front Pediatr, 2022, 10: 814461.
[20] Chen T, Fan C, Huang Y, et al. Genomic sequencing as a first-tier screening test and outcomes of newborn screening[J]. JAMA Network Open, 2023, 6(9): e2331162.
[21] Kubaski F, Mason RW, Nakatomi A, et al. Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry[J]. J Inherit Metab Dis, 2017, 40(1): 151-158.
文章导航

/